Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Alzheimer's drug trial halted early – what we know

NCT ID NCT03919162

Disease control Sponsor: Vivoryon Therapeutics N.V. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called varoglutamstat (PQ912) in people with early Alzheimer's disease. The goal was to see if it is safe and if it could slow memory and thinking problems. The trial was stopped early, so we have less information than planned. About 112 people took part, receiving either the drug or a placebo for at least 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
varoglutamstat (PQ912)
What this could lead to
If it works, this could slow cognitive decline in early Alzheimer's disease.
What could go wrong
The trial was terminated early, so results are limited. It is still in early phases, and many Alzheimer's drugs fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

112 people

The number who actually took part.

Started

Nov 2021

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Age 50-89 (inclusive) at screening * Diagnosed as having Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) or Mild probable AD according to workgroups of the Diagnostic Guidelines of the National Institute on Aging and Alzheimer's Association (NIA-AA) * Mini-Mental State Examination (MMSE) score 20-30 inclusive at screening * Montreal Cognitive Assessment score (MoCA) \< 26 at screening * Clinical Dementia Rating global score 0.5 or 1 with memory score of \> 0.5 at screening * Positive cerebrospinal fluid (CSF) AD biomarker signature * A brain MRI scan within 6 months of screening consistent with a diagnosis of Alzheimer's disease * Participants must have a study partner who has frequent interaction with them (approximately \>3-4 times per week), will be present for all clinic visits, and can assist in compliance with study procedures. Key Exclusion Criteria: * Significant neurodegenerative diseases and causes of dementia, other than AD, including Parkinson's disease and Huntington's disease, vascular dementia, CJD (Creutzfeldt-Jakob disease), LBD (Lewy Body dementia), PSP (Progressive Supranuclear Palsy), AIDS (Acquired Immunodeficiency Syndrome), or NPH (normal pressure hydrocephalus) * Meeting Diagnostic Criteria for Possible AD according to workgroups of the Diagnostic Guidelines of the NIA-AA * Hepatic impairment defined as Child-Pugh class A or more severe liver impairment * History of moderate or severe skin reactions to medications or current moderate or severe disease of the skin and subcutaneous tissues * History of a major depressive episode within the past 6 months of screening * History of diagnosis of schizophrenia * History of uncontrolled bipolar disorder within past five years of screening * History of seizures within past two years of screening * Contraindication to lumbar puncture and MRI * Monoclonal antibody treatment with anti-amyloid or anti-tau agents intended to address the pathophysiologic processes associated with AD within the previous 180 days prior to baseline (BL) * Participants who are planning to receive treatment with aducanumab or any Amyloid Beta Antibody during the course of the study * Participation in another clinical trial for an investigational agent and having taken at least one dose of study drug, unless confirmed as having been on placebo, within 90 days prior to the baseline visit. The end of a previous investigational trial is defined as the date of the last dose of an investigational agent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease

Contacts and locations

Locations

  • Abington Neurological Associates

    Abington, Pennsylvania, 19001, United States

  • Banner Sun Health Research Institute

    Sun City, Arizona, 85351, United States

  • Barrow Neurological Institute

    Phoenix, Arizona, 85013, United States

  • Cedars-Sinai Center

    Los Angeles, California, 90048, United States

  • Emory University

    Atlanta, Georgia, 30329, United States

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, 20057, United States

  • Lowcountry Center for Veterans Research (LCVR)

    Charleston, South Carolina, 29403, United States

  • NYU Langone Health Tisch Hospital

    New York, New York, 10016, United States

  • Northern Light Acadia Hospital

    Bangor, Maine, 04401, United States

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois, 60611, United States

  • OHSU Neurology Clinic

    Portland, Oregon, 97239, United States

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • PCND Neurology

    Poway, California, 92064, United States

  • Rhode Island Hospital

    Providence, Rhode Island, 02903, United States

  • SUNY Upstate Medical University

    Syracuse, New York, 13210, United States

  • The Neuron Clinic

    Chula Vista, California, 91910, United States

  • The University of Iowa Carver College of Medicine

    Iowa City, Iowa, 52242, United States

  • The University of Kentucky Sanders-Brown Center on Aging

    Lexington, Kentucky, 40504, United States

  • UCSD Alzheimer's Disease Research Center

    La Jolla, California, 92037, United States

  • USF Health Byrd Alzheimer's Center and Research Institute

    Tampa, Florida, 33613, United States

  • UT Health San Antonio

    San Antonio, Texas, 78229, United States

  • University of California

    Irvine, California, 92868, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.